Streetbeat News

Stock Prices

ADI

Analog Devices, Inc. (NASDAQ:ADI) reported better-than-expected Q3 earnings, with revenue and EPS beating analyst estimates. Despite a year-on-year revenue decline, the company sees improved inventory and order momentum for Q4, projecting revenue and EPS above consensus. ADI stock rose 4.70% premarket.

Portfolio Pulse from Anusuya Lahiri

August 21, 2024 | 12:01 pm

TMDX

TransMedics Gr (NASDAQ:TMDX) has received 10 analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased by 30.84% to $169.6. Analysts have raised their price targets, reflecting positive sentiment towards the company's financial performance, including a 117.87% revenue growth rate and strong profitability metrics. However, the company faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

August 21, 2024 | 12:01 pm

EPRT

Essential Props Realty (NYSE:EPRT) has received mixed analyst ratings over the past three months, with a majority being bullish. Analysts have set a 12-month average price target of $32.0, up 11.46% from the previous target. The company shows strong financial performance with impressive revenue growth, net margin, ROE, and ROA, and maintains a sound debt management structure.

Portfolio Pulse from Benzinga Insights

August 21, 2024 | 12:01 pm

BBAI

KEYS

TGT

Target, BigBear.ai, and Keysight Technologies have all reported positive news. Target's Q2 2024 earnings and sales exceeded estimates. BigBear.ai received a significant subcontractor award, and Keysight Technologies reported better-than-expected Q3 results.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 12:01 pm

FIVN

Analysts have mixed views on Five9 (NASDAQ:FIVN), with recent ratings showing a decline in price targets. The average 12-month target is now $60.5, down 25.82% from previous estimates. Despite strong revenue growth, Five9's financial metrics like net margin and ROE are negative, and its debt-to-equity ratio is high, indicating financial risk.

Portfolio Pulse from Benzinga Insights

August 21, 2024 | 12:01 pm

NNN

NNN REIT (NYSE:NNN) has been analyzed by six analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased to $45.33, with a high of $49.00 and a low of $41.00. Recent analyst actions include several rating raises and one downgrade. NNN REIT has shown strong revenue growth and profitability, but faces challenges with its return on equity.

Portfolio Pulse from Benzinga Insights

August 21, 2024 | 12:01 pm

GLW

Corning (NYSE:GLW) has received 22 analyst ratings over the past three months, with a mix of bullish and indifferent sentiments. The average 12-month price target has increased to $44.45, indicating positive expectations. Analysts have adjusted their ratings and price targets, reflecting their response to Corning's market performance and financial indicators. Corning shows strong financial performance with impressive revenue growth, net margin, ROE, and ROA, but has a higher debt-to-equity ratio than industry averages.

Portfolio Pulse from Benzinga Insights

August 21, 2024 | 12:00 pm

FAS

FAZ

GS

JPM

MA

PGR

V

The article discusses the potential for lower interest rates by the Federal Reserve amid economic challenges, highlighting the performance of financial institutions and leveraged ETFs. JPMorgan Chase, Goldman Sachs, Visa, and Mastercard have shown resilience, while Progressive Corp indicates a flight to safety. Direxion's leveraged ETFs, FAS and FAZ, offer speculative opportunities in this uncertain market environment.

Portfolio Pulse from Joshenomoto@benzinga.com

August 21, 2024 | 11:58 am

AADI

Aadi Bioscience shares fell after an Independent Data Monitoring Committee analysis indicated that their study is unlikely to meet the efficacy threshold for accelerated approval. The company is pausing new enrollment and cutting its R&D workforce by 80%.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:58 am

ANEW

ANEW MEDICAL shares rose following the announcement of an exclusive worldwide license agreement with Transfertech Sherbrooke for Nanoject.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 11:56 am